Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Leerink’s Jason Gerberry: deal is strategically important as it boosts rare disease drugs to about 65% of combined portfolio, cementing rare-disease leadership.
Leerink’s Michael Schmidt: Shire discontinued Baxalta’s BAX-335 hemophilia B gene therapy post-acquisition, raising questions about pipeline value embedded in…
Shire shares fell 9% on announcement. Wall Street questioned whether Shire paid too much given fierce hemophilia competition from Biogen, Roche, and BioMarin.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Shire acquired Baxalta for $32B for rare disease and hematology.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / Baxalta Inc. (this deal) | 2016 | $32.0B | 77 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
| Shire plc / Movetis NV | 2010 | $565M | 37 |
← Browse all deals · How we score deals
More: 2016 deals · Shire plc deals · Hematology deals